Bio-Techne Corporation (TECH) P/E Ratio History
Historical price-to-earnings valuation from 1990 to 2026
Loading P/E history...
TECH Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Bio-Techne Corporation (TECH) trades at a price-to-earnings ratio of 103.1x, with a stock price of $47.41 and trailing twelve-month earnings per share of $0.70.
The current P/E is 35% above its 5-year average of 76.3x. Over the past five years, TECH's P/E has ranged from a low of 39.7x to a high of 129.2x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, TECH trades at a 365% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, TECH commands a significant premium over the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TECH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TECH P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 146.2 | - | +287% | |
| $11B | 47.6 | - | -14% | |
| $176B | 26.7 | 12.62 | +7% | |
| $124B | 34.7 | - | -5% | |
| $22B | 26.2 | 6.18 | +171% | |
| $7B | 9.3Lowest | - | +143% | |
| $7B | 16.9 | 0.38Best | +437%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
TECH Historical P/E Data (1990–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | $52.26 | $0.69 | 75.7x | +87% | |
| FY2026 Q2 | Wed Dec 31 2025 00:00:00 GM | $58.81 | $0.51 | 115.3x | +185% |
| FY2026 Q1 | $55.63 | $0.49 | 113.5x | +180% | |
| FY2025 Q4 | Mon Jun 30 2025 00:00:00 GM | $51.45 | $0.46 | 111.8x | +176% |
| FY2025 Q3 | Mon Mar 31 2025 00:00:00 GM | $58.63 | $0.82 | 71.5x | +77% |
| FY2025 Q2 | $72.03 | $0.99 | 72.8x | +80% | |
| FY2025 Q1 | Mon Sep 30 2024 00:00:00 GM | $79.93 | $0.94 | 85.0x | +110% |
| FY2024 Q4 | Sun Jun 30 2024 00:00:00 GM | $71.65 | $1.04 | 68.9x | +70% |
| FY2024 Q3 | Sun Mar 31 2024 00:00:00 GM | $70.39 | $1.26 | 55.9x | +38% |
| FY2024 Q2 | Sun Dec 31 2023 00:00:00 GM | $77.16 | $1.38 | 55.9x | +38% |
| FY2024 Q1 | Sat Sep 30 2023 00:00:00 GM | $68.07 | $1.52 | 44.8x | +11% |
| FY2023 Q4 | Fri Jun 30 2023 00:00:00 GM | $81.63 | $1.76 | 46.4x | +15% |
Average P/E for displayed period: 40.5x
See TECH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TECH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TECH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTECH — Frequently Asked Questions
Quick answers to the most common questions about buying TECH stock.
Is TECH stock overvalued or undervalued?
TECH trades at 103.1x P/E, above its 5-year average of 76.3x. The 75th percentile ranking indicates a premium to historical valuation.
How does TECH's valuation compare to peers?
Bio-Techne Corporation P/E of 103.1x compares to sector median of 22.1x. The premium reflects expected growth above peers.
What is TECH's PEG ratio?
TECH PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1990-2026.